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1. Introduction 
Group B streptococcus (GBS), also known as Streptococcus agalactiae is a Gram-positive, ǃ-
hemolytic, chain-forming bacterium and a commensal within the genital tract flora in 
approximately 25% of healthy adult women (Campbell et al., 2000). The organism is a 
leading cause of serious infection in newborns, pregnant women, and older persons with 
chronic medical illness (Baker et al., Edwards&Baker, 2005). In neonates GBS infection most 
commonly causes pneumonia, meningitis, and sepsis. In addition to maternal 
cervicovaginal colonization and neonatal infection that can result from vertical transmission 
of GBS from mothers to their infants, the bacterium can also cause urinary tract infection 
(UTI). The spectrum of GBS UTI includes asymptomatic bacteriuria (ABU), cystitis, 
pyelonephritis, urethritis, and urosepsis (Bronsema et al., 1993, Edwards&Baker, 2005, 
Farley et al., 1993, Lefevre et al., 1991, McKenna et al., 2003, Munoz et al., 1992, Ulett et al., 
2009). GBS ABU is particularly common among pregnant women, although those most at 
risk for cystitis due to GBS appear to be elderly individuals (Edwards&Baker, 2005, Falagas 
et al., 2006, Muller et al., 2006). In addition to acute and asymptomatic UTI other invasive 
diseases caused by GBS infection include skin infections, bacteraemia, pneumonia, arthritis, 
and endocarditis (Liston et al., 1979, Patil&Martin, 2010, Tissi et al., 1997, Trivalle et al., 
1998). Thus, GBS is considered unique in terms of its ability to cause a spectrum of diseases 
in newborns and adult humans and its ability to colonize the genital tract of healthy women 
in a commensal-type manner. In contrast to GBS disease conditions resulting from neonatal 
infection, the clinical and microbiological features of GBS UTI and asymptomatic genital 
tract colonization are not well characterized. Moreover, the risk factors for the various 
diseases caused by GBS including UTI and the pathogenesis of the different diseases caused 
as a result of GBS infection are not well defined. 
Recent advances in the awareness, diagnosis and treatment of GBS infections, particularly in 
relation to vertical transmission and neonatal infection, have significantly reduced mortality 
in the newborn population. Establishment of preventative and treatment guidelines by the 
Centres for Disease Control (CDC) beginning in the 1990s has resulted in a reduction in 
mortality rates due to acute GBS infection in newborns from approximately 30-50% to 4–5% 
(Dermer et al., 2004). Guidelines for the prevention of GBS infections in newborns first 
published in 1992 and revised in 1997 include surveillance programs and administration of 
antibiotics during labour (intrapartum antibiotic chemoprophylaxis) (1992, 1997). Since the 
mid-1990s, most pregnant women in the United States have been screened for infection by 
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GBS and the success of intrapartum antibiotic chemoprophylaxis for the prevention of 
vertical transmission of GBS has been noted (Verani et al., 2010). However, preventive 
strategies to identify at-risk individuals are controversial and the rates of GBS-related 
stillbirths, prematurity, and late onset disease (LOD) have not decreased (Gibbs et al., 2004). 
The incidence of morbidities in newborn survivors of acute GBS infection ranges from 20–
60% and includes neurological sequelae (Gibbs et al., 2004, Lukacs et al., 2004). The manner 
in which specific preventative strategies are implemented may also affect disease prevalence 
due to GBS in some areas (Krasnianin et al., 2009, Rausch et al., 2009). Thus, infections due 
to GBS and the ensuing diseases that result remain a significant cause of morbidity and 
mortality in newborns as well as healthy adults (Berner, 2004, van der Poll&Opal, 2008). 
In addition to representing a major infection risk for neonates and pregnant women GBS is 
also a prominent pathogen of the elderly, immunocompromised, and individuals with 
diabetes and malignancies. These populations are particularly at risk for invasive GBS 
infection (Edwards&Baker, 2005, Farley, 2001). The manifestations of GBS infection in these 
populations are highly varied; however, some of the most common clinical presentations 
include skin and soft tissue infections, bacteraemia, pneumonia, arthritis, UTI, and 
endocarditis (Baker, 1997, Farley, 2001, Lee et al., 2007, Trivalle et al., 1998). The case fatality 
rate for GBS infection in elderly adults was estimated to be approximately 15% in the United 
States between 2001 and 2005 (Edwards&Baker, 2005, Farley, 2001). Importantly, there is no 
vaccine currently available to prevent GBS disease in neonates or adults despite a 
substantial research effort in identifying potential immunogens as vaccine candidates in 
immunization strategies (Doro et al., 2009).  
The recent emergence of GBS strains that are resistant to multiple antibiotics represents a 
significant concern in the treatment of these infections in adults and children (Andrews et 
al., 2000, Bland et al., 2001, Dahesh et al., 2008, Heelan et al., 2004, Kimura et al., 2008, 
Nagano et al., 2008, Simoes et al., 2004). Penicillin-derived antibiotics remain the drugs of 
choice for treatment of GBS infections in infants and adults (Sendi et al., 2008, 
Verani&Schrag, 2010). These antibiotics inhibit cell wall synthesis during active growth of 
the bacteria. Vancomycin, cefezolin, clindamycin and telavancin are also used for the 
treatment of GBS infections. Trends of increasing antibiotic resistance (Edwards, 2006) may 
reflect clonal dissemination and horizontal transfer of resistance genes, which occurs among 
some GBS isolates (Puopolo et al., 2007). In addition, the identification of GBS strains 
resistant to penicillin, clindamycin and erythromycin represents a significant concern for the 
treatment of infections (Andrews et al., 2000, Bland et al., 2001, Dahesh et al., 2008, Heelan et 
al., 2004, Kimura et al., 2008, Nagano et al., 2008, Simoes et al., 2004). A large number of 
microbiological studies on GBS infection over the past two decades have underscored the 
importance of GBS as a major public health concern and a need for improvements in 
preventative and therapeutic strategies. An improved understanding of the mechanisms of 
GBS disease pathogenesis is vital for such strategies. 
1.1 Host range and GBS serotypes 
GBS was once seen only as a veterinary pathogen. The organism was originally isolated 
from cattle in the 1930s and prior to the 1980s was regarded as a prominent cause of bovine 
mastitis in dairy cows. Indeed, the species name, agalactiae, translates to "no milk" and 
reflects this history. Subsequently, epidemiology and prevalence studies indicated that GBS 
was associated with disease in neonates and the bacterium was increasingly recognized 
beginning in 1977 as a major cause of postpartum infection in human newborns (Ferrieri et 
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al., 1977). GBS is now universally accepted as among the most common causes of neonatal 
sepsis and meningitis. Research in the mid-1980s demonstrated that GBS was carried in the 
genital tract and the gastrointestinal flora in up to 30% of healthy adult women, which 
reflected intermittent, transient, or persistent colonization (Boyer et al., 1983, Dillon et al., 
1982). Over the last fifteen years studies have demonstrated that GBS is a significant cause of 
serious disease in non-pregnant adults including elderly people and immunocompromised 
individuals. Emerging trends in GBS disease incidence and prevalence strongly suggest that 
changes in the recognition and treatment of GBS infections are impacting the types of 
individuals affected by the bacterium and invasive disease in adults is now more common 
than in neonates (Baker, 2000. , Falagas et al., 2006, Muller et al., 2006).  
There are ten different capsular serotypes of GBS, namely Ia, Ib, and II-IX. These are based 
on the structure of the surface polysaccharide capsule of the bacterium. Nontypeable GBS 
also exist and are associated with some infections in humans including UTI (Baker&Barrett, 
1974, McKenna et al., 2003, Persson et al., 1985). Capsular serotyping of GBS can be 
performed by latex agglutination using commercial antisera (Slotved et al., 2003), which 
differentiates the major Lancefield groups (Facklam, 2002) based on serotype-specific 
antibody-based binding. Molecular serotyping (MS) methods have gained popularity and 
can provide additional insight into serotype traits that are not able to be derived from 
antisera-based approaches, possibly as a result of limited antigen expression in some strains 
(Ferrieri et al., 2004, Kong et al., 2002, Manning et al., 2008, Ramaswamy et al., 2006, Wen et 
al., 2006). MS identification of all ten serotypes is possible (MS Ia, Ib, and II-IX) with the use 
of a multiplex PCR and reverse line blot hybridization assay targeting a GBS species-specific 
gene (cfb) and serotype-specific sequences in various other capsular loci genes (Kong et al., 
2005). Among the ten different types, the serotypes most frequently associated with serious 
disease are serotypes Ia, II, III, and V (Edwards&Baker, 2005). There is some evidence to 
suggest that switching can occur between capsular types in GBS (Martins et al., 2010). 
1.2 GBS disease spectrum and Co-morbidities 
GBS is a frequent cause of puerperal infections including pneumonia, sepsis, meningitis, 
amnionitis and endometritis. These infections are common in newborns, pregnant women, 
and adults with underlying medical conditions (Nizet et al., 2000, Pass et al., 1982). Diabetes 
mellitus and malignancy are among the most common underlying conditions associated 
with these GBS infections (Huang et al., 2006). Other co-morbidities that have been 
associated with GBS disease in adults include cardiovascular abnormalities, genitourinary 
disorders, neurologic deficits, cirrhosis, steroid use, AIDS, renal dysfunction, and peripheral 
vascular disease. Relapse of GBS disease in affected individuals is not uncommon, with 
approximately 5% of non-pregnant adults experiencing a second episode of GBS disease 
after resolution of the primary infection (Sendi et al., 2008). The pathogenic basis of this 
recurrence is unknown but it is nonetheless an important consideration clinically.  
The nature of GBS as a frequent constituent of the resident vaginal bacterial microflora in 
healthy adult women means that the bacterium is regarded as a normal commensal under 
these circumstances. Colonized women often carry GBS for long periods of time and usually 
do not show clinical symptoms as a result of persistent genital tract infection. On the other 
hand, conditions during pregnancy may lead to increased GBS multiplication in the 
urogenital tract and GBS can grow to high numbers in human amniotic fluid. This may lead 
to serious consequences for both the colonized mother and the infant. Between 15%-45% of 
pregnant women harbour GBS in the gastrointestinal and or genitourinary tracts (Schuchat, 
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1998); neonates acquire the bacteria at birth from their asymptomatically colonized mothers 
in approximately 1% of all live births (Baker, 2000. , Nandyal, 2008, Schuchat, 1998). The 
neonatal lung can receive a substantial inoculum from infected amniotic fluid at birth (Nizet 
et al., 2000). In addition, GBS may be acquired by the growing fetus prior to birth in utero, 
which can trigger adverse pregnancy outcomes. Thus, GBS continues to be an important 
perinatal pathogen but causes a wide spectrum of diseases that is associated with various 
co-morbidities.  
1.3 Detection and identification of GBS 
The majority of GBS infections can be diagnosed through routine laboratory testing of 
clinical samples such as blood, cerebrospinal fluid, or aspirates from sites of local 
suppuration. In the majority of cases isolates are rapidly identified by typical colony 
morphology on agar medium such as tryptic soy agar-5% sheep blood, and are tested for 
catalase, which streptococci do not express. Isolates are grouped into the Lancefield B group 
(Facklam, 2002) using commercial typing antisera for latex agglutination assays. GBS 
antigens can occasionally be detected in blood, cerebrospinal fluid, and urine but are not 
routinely tested for in any diagnostic assays. A Gram stain of a clinical specimen can be 
useful in the detection of infection but is not specific and therefore not definitive for 
identification. Polymerase chain reaction and optical immunoassay may, on the other hand, 
provide rapid and specific results for the detection of GBS infection; however, optimization 
and validation of these assays to ensure sensitivity and specificity has limited their 
widespread application in the clinical laboratory (Daniels et al., 2009, Schwope et al., 2010).  
1.4 GBS virulence factors and host cell responses 
A number of GBS virulence factors that contribute to disease and infection in the host have 
been discovered. The role of these GBS virulence factors in UTI remains unexplored. A 
number of exotoxigenic virulence factors are produced by GBS, including hyaluronate lyase, 
Christine Atkins Munch Peterson (CAMP) factor, superoxide dismutase, proteases, 
nucleases, platelet-activating factor, collagenase/oligopeptidase, protein c, RIB, R protein, 
and C5a peptidase (Lindahl et al., 2005, Liu&Nizet, 2004, Nizet et al., 2000). The functions 
and structures of several of these virulence factors are reviewed elsewhere (Liu&Nizet, 
2004). One of the major GBS virulence factor is the sialic acid-rich capsular polysaccharide, 
which has been extensively studied as a virulence factor for many years (Slotved et al., 
2007). Capsular polysaccharide is anti-phagocytic and influences the pathogenicity of GBS 
by mediating evasion of phagocytes (Adderson et al., 2000). GBS lipotechoic acid (LTA) is 
another key virulence factor that contributes to successful infection in the host. GBS LTA is 
cytotoxic to human monocytes and induces inflammation including the production of pro-
inflammatory cytokines such as TNF-ǂ (Berner, 2002). Cytotoxicity including the ability to 
induce programmed cell death (PCD) in host cells may contribute to disease by promoting 
adhesion, invasion, and host immune-evasion (Nizet et al., 2000). ǃ-hemolysin is produced 
in varying amounts by virtually all clinical isolates of GBS and has several known roles in 
virulence including cytotoxicity (Liu&Nizet, 2004, Nizet et al., 2000). ǃ-hemolysin is 
expressed on the surface of GBS and is responsible for the characteristic ǃ-hemolytic activity 
on blood agar (Nizet, 2002, Nizet et al., 2000). ǃ-hemolysin has a role in early but not late 
PCD and its expression is abolished by glucose (Fettucciari et al., 2000, Ulett et al., 2003). 
Several virulence factors of GBS including LTA, ǃ-hemolysin, C5a peptidase and the R 
protein/antigen are involved in recognition by host cells and inducing or evading immune 
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responses (Cheng et al., 2001, Fasola et al., 1996, Henneke et al., 2005, Liu et al., 2004). The 
proficiency of GBS recognition by macrophages is considered a crucial component of early 
immune responses against the bacteria (Chattopadhyay et al., 2011, Franke-Ullmann et al., 
1996, Jonsson et al., 1985, Sherman et al., 1992, Sibille&Reynolds, 1990). However, GBS are 
able to persist inside macrophages for an extended period of time after nonopsonic 
phagocytosis and eventually trigger death of the host cell (Cornacchione et al., 1998, 
Fettucciari et al., 2000, Ulett et al., 2003, Valenti-Weigand et al., 1996). Intracellular 
persistence and manipulation of death pathways in macrophages may represent a virulence 
mechanism whereby GBS contributes to the characteristically poor inflammatory response 
in the neonatal lung. GBS-induced cell death is also a prominent feature of hepatocytes in a 
rabbit model of GBS sepsis (Ring et al., 2002) and in neurons of the dentate gyrus in GBS 
meningitis (Bogdan et al., 1997).  
2. Bacterial UTI: general aspects 
Ten to forty percent of adult women will contract at least one UTI in their lifetime, and 
approximately 3% will experience more than one infection per year (Andriole&Patterson, 
1991, Patton et al., 1991, Foxman, 2002). UTI are the second most common infectious 
diseases in humans after respiratory tract infections, and contribute to approximately 60 
million hospital visits per year. The costs to health care systems have been estimated at over 
$2 billion annually (Andriole&Patterson, 1991, Barnett&Stephens, 1997, Hooton&Stamm, 
1997, Patton et al., 1991). Chronic UTI are difficult to prevent and treat, and infections are 
often recurrent. Over 80% of UTI are caused by uropathogenic Escherichia coli (UPEC) 
(Ronald, 2002). Approximately 2% of UTI are caused by GBS. Among an estimated 40% of 
all adult women who will experience a UTI episode in their lifetime almost 1% will suffer 
UTI caused by GBS (Foxman, 2002). The urinary tract is a distinct mucosal surface of the 
body and bacterial colonization of the uroepithelium is unique compared to other mucosal 
surfaces. Colonizing bacteria must overcome the normal flushing actions of urine flow and 
the physical barrier of the uroepithelial lining. This lining embodies a tightly interlaced 
latticework of proteins called uroplakins (Apodaca, 2004). These are closely associated with 
a collection of lipids, sphingolipids, and cholesterol referred to as lipid rafts that 
cumulatively constitute a surface that is highly impregnable to urine, solutes, and potential 
pathogens such as UPEC and GBS (Apodaca, 2004). 
2.1 Prevalence of GBS in the urinary tract 
The spectrum of UTI caused by GBS includes ABU, cystitis, pyenorephritis, urethritus, and 
urosepsis (Bronsema et al., 1993, Farley et al., 1993, Lefevre et al., 1991, McKenna et al., 2003, 
Munoz et al., 1992). In many cases, GBS colonization of the urinary tract in women probably 
occurs by an ascending route from the vagina, where GBS can persist asymptomatically. 
GBS is cultured from approximately 2% of all UTI cases (de Mouy et al., 2007, Munoz et al., 
1992, Persson et al., 1988). In the most recent single-centre analysis of adult patients in the 
United States GBS was cultured from urine during routine assessment for UTI in 2% of 
patients; most of these represented ABU (Ulett et al., 2009). This is consistent with findings 
in other studies (Aungst et al., 2004, Le et al., 2004). However, several studies have reported 
high rates of GBS UTI in non-pregnant adults (Edwards&Baker, 2005, Falagas et al., 2006, 
Muller et al., 2006, Toumi et al., 2006). In one study, GBS was cultured from 39% of all cases 
of symptomatic UTI among nursing home residents >70 years of age (Trivalle et al., 1998). 
www.intechopen.com
 Clinical Management of Complicated Urinary Tract Infection 
 
56
Other studies have reported that GBS UTI may account for up to one-third of all invasive 
infections due to GBS in elderly adults (Falagas et al., 2006, Hernaiz et al., 2004, Lefebvre et 
al., 2007, Munoz et al., 1992) and up to 7% of late-onset disease in neonates (Yagupsky et al., 
1991). Urinary tract abnormalities, chronic renal failure (Munoz et al., 1992), 
diabetes mellitus (Ronald, 2003), corticosteroid use (Falagas et al., 2006), and prior UTI (Ulett 
et al., 2009) are among risk factors for GBS UTI.  
2.2 GBS ABU and UTI in pregnancy 
While the overall prevalence of GBS UTI remains unclear, GBS bacteriuria during pregnancy 
occurs at rates of between 1 and 3.5% (Baker, 1997, McKenna et al., 2003, Whitney et al., 
2004). Approximately 2-7% of pregnant women exhibit ABU caused by GBS and GBS ABU 
during pregnancy is considered a surrogate marker for heavy maternal genital tract 
colonization (Liston et al., 1979, McKenna et al., 2003, Moller et al., 1984, Persson et al., 
1986a, Wood&Dillon, 1981) and is indicated for intrapartum antibiotic chemoprophylaxis 
(McKenna et al., 2003, Schrag et al., 2002). In addition, up to 7% of pregnancies may be 
complicated by GBS UTI, and GBS reportedly accounts for approximately 10% of all cases of 
pyelonephritis during pregnancy (Muller et al., 2006, Persson et al., 1986a, Persson et al., 
1986b). GBS UTI may also contribute to chorioamnionitis (Anderson et al., 2007), premature 
onset of labour (Moller et al., 1984), and an increased risk of vertical transmission of GBS  
(Persson et al., 1985, Wood&Dillon, 1981). Stemming from this, maternal GBS ABU 
(including pure and predominant growth of GBS in the urine) has been associated with 
vertical transmission and an increased risk for early-onset disease (EOD) in newborn infants 
(Heath et al., 2009, Liston et al., 1979, Moller et al., 1984, Persson et al., 1986a, Persson et al., 
1985, Wood&Dillon, 1981). One study found an elevated risk for EOD among infants born to 
women with low colony-count GBS ABU compared with mothers who did not have GBS 
ABU (Weng et al., 2010). However, studies have also demonstrated that some women with 
GBS ABU during the first trimester of pregnancy may not exhibit vaginal-rectal colonization 
at 35-37 weeks gestation (McKenna et al., 2003) or at the time of delivery (Edwards et al., 
2002). Thus, while maternal ABU does not necessarily lead to vertical transmission, ABU at 
any point during pregnancy may be a risk factor for neonatal EOD and has therefore been 
an indication for intrapartum antibiotic chemoprophylaxis since 1996 (Schrag et al., 2002, 
Yancey et al., 1996). ABU may also be an indicator of potential preterm labour (Schrag et al., 
2002, Yancey et al., 1996). The American College of Obstetricians and Gynecologists (ACOG) 
and CDC guidelines recommend the evaluation of pregnant women at 35-37 weeks 
gestation and antibiotic therapy for women with positive cultures for GBS ABU. The 1996 
ACOG and CDC guidelines do not specify a colony-count threshold for defining GBS ABU. 
However, the 2002 and more recent guidelines recommend reporting of GBS at any 
concentration in urine (Lin&Fajardo, 2008). Finally, although pregnant women may receive 
antibiotics to treat GBS ABU this therapy may not eliminate GBS from the genitourinary 
tract, and recolonization after a course of antibiotics can occur (Baecher&Grobman, 2008, 
Gardner et al., 1979, Hall et al., 1976). 
Most data on the risk for EOD among infants born to women with GBS ABU are derived 
from studies using thresholds >105 cfu/ml despite lower counts of 103 cfu/ml having been 
associated with acute GBS UTI (Persson et al., 1986b, Persson et al., 1985, Ulett et al., 2009, 
Wood&Dillon, 1981). Although low concentrations (103-104 cfu/ml) of GBS in urine can be 
associated with colonization (Centelles-Serrano et al., 2009) limited data support the risk for 
EOD among infants born to women with low colony-count GBS ABU (Persson et al., 1986a). 
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The recommendation to report any colony count of GBS in urine represents increased 
workload for clinical laboratories, which generally do not report bacterial growth in urine of 
other pathogens at concentrations <104 cfu/ml (McCarter et al., 2009) and rarely know 
whether urine samples are from pregnant women. In the context of universal late antenatal 
GBS  screening, it is unclear how much EOD is prevented by screening for low colony-count 
GBS ABU and whether identification of low colony-count bacteriuria is cost-effective. 
2.3 Diagnosis of GBS UTI 
Diagnostic strategies for UTI vary substantially between clinicians (Hay&Fahey, 2002, 
Kaufmann&Modest, 2002, Libbus, 2002); however, patients with a combination of symptoms 
have a high probability of UTI (Bent et al., 2002, Nicolle, 2008). Pyuria concurrently with 
bacteriuria constitutes diagnostic criteria in some settings (Shaikh et al., 2007), although 
what constitutes clinically significant bacteriuria is not strictly defined; colony counts 
>103 cfu/ml of a uropathogen is however, now widely accepted diagnostic criteria for 
cystitis (Nicolle, 2008, Rubin et al., 1992). Clinically, UTI due to GBS may be 
indistinguishable from UTI caused by other uropathogens (Muller et al., 2006). A recent 
study of multiple uropathogens highlighted unique frequencies of host characteristics in UTI 
groups defined by the causal organism (Tabibian et al., 2008). This suggests that the clinical 
and microbiological features of UTI may differ depending on the infecting pathogen and the 
most ideal diagnostic approaches may depend on the causal organism. In one study the 
investigators regarded single-organism GBS bacteriuria and at least one UTI symptom as 
being a probable case of UTI  and used urinary leukocyte esterase with pyuria as 
confirmatory for diagnosis (Ulett et al., 2009). Here, a provisional diagnosis was defined by 
the presence of single-organism GBS bacteriuria (>104 cfu/ml) with at least one symptom 
that included dysuria, increased urinary frequency and/or urgency, fever of >38°C, flank 
pain, and/or lumbar tenderness. In cases where urinalysis (UA) was performed, UTI was 
confirmed on the basis of positive urinary leukocyte esterase and significant pyuria 
(≥107 white blood cells/high-power field; non-spun). These are the generally accepted 
criteria for the diagnosis of UTI (Hay&Fahey, 2002, Kaufmann&Modest, 2002, Libbus, 2002) 
although inclusion of bacteriuria counts of >103 cfu/ml may provide additional clinical 
relevance. In this study group, patients were grouped into probable GBS UTI where UA was 
not performed and confirmed cases where (positive) UA data were available. Individuals 
defined as having GBS isolated from urine incidentally were selected on the basis of low-
grade GBS bacteriuria (<104 cfu/ml) in the absence of symptoms. In this study, multiple 
patients were identified who had symptoms of UTI and positive UA findings but had GBS 
bacteriuria counts between 103-105 cfu/ml, which is consistent with reports that up to 30% of 
women with cystitis present with bacteriuria of <105 cfu/ml. Thus, the level of bacteriuria in 
GBS UTI may not correlate well with acute disease. The serotypes of GBS associated with 
UTI have not been well defined; however it appears that most serotypes can cause acute 
UTI. MS and antisera-based serotyping was used in one study to identify the serotypes 
associated with UTI (Ulett et al., 2009), and demonstrated a predominance of serotypes Ia, II, 
III, and V in patients with acute UTI. Other studies demonstrated that nontypeable GBS also 
cause acute UTI (McKenna et al., 2003, Persson et al., 1985).  
2.4 How does GBS colonize the urogenital tract?  
GBS infection often begins with binding to epithelial cells at mucosal surfaces, such as those 
lining the respiratory or urogenital tracts. GBS are able bind to human vaginal epithelial 
cells under low pH conditions, which are characteristic of vaginal mucosa. These 
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interactions occur via low avidity interactions of cell-wall-associated LTA and via higher-
affinity interactions mediated by hydrophobic GBS surface proteins (Tamura et al., 1994). 
Many of these host-cell interactions involve attachment of GBS to extracellular matrix 
molecules such as fibronectin, fibrinogen and laminin, which in turn bind host-cell-surface 
proteins such as integrins (Maisey et al., 2008). For example, ScpB, which is a GBS cell-
surface protein previously characterised for its ability to cleave the complement-derived 
chemoattractant C5a (Beckmann et al., 2002), can bind fibronectin (Cheng et al., 2002). ScpB 
can bind to integrins, which may promote both binding to host cells and complement 
proteolysis (Brown et al., 2005). Naturally occurring ScpB variants with a deletion that 
destroys peptidase function retain the capacity to bind fibronectin (Cleary et al., 2004, 
Tamura et al., 2006). GBS attachment to fibrinogen is mediated by the surface-anchored 
protein FbsA (Schubert et al., 2004), and adherence to laminin involves the adhesin Lmb 
(Spellerberg et al., 1999). The serine-rich repeat domain protein Srr-1 binds human keratin 4 
(Samen et al., 2007) and the GBS surface protein LrrG, containing the leucine-rich-repeat 
motif found in many invasins, binds to epithelial cells, suggesting that it serves as an 
adhesin during GBS infection (Seepersaud et al., 2005). In each of these examples, these 
binding interactions probably promote GBS adherence to epithelial cells.  
GBS were also recently shown to express pili (Lauer et al., 2005), which typically facilitate 
Gram-negative bacterial attachment to host cells (Sauer et al., 2000). Among eight sequenced 
GBS genomes, two genetic loci encoding pili were identified, the second existing in one of 
two variants, although not all genomes contain both loci (Rosini et al., 2006). GBS pilus 
island 2’ includes the genes encoding PilB, an LP(x)TG-motif-containing protein that 
polymerises to form a pilus backbone, and accessory pilus proteins PilA and PilC (Dramsi et 
al., 2006, Maisey et al., 2007). Epithelial cell adherence is reduced in isogenic GBS mutants 
lacking PilA or PilC, but not those lacking PilB (Dramsi et al., 2006). The role of GBS pili in 
binding in the urogenital tract is unknown.  
2.5 Modeling GBS UTI from clinical studies   
Uropathogenic GBS (UPGBS) have been shown to bind to both murine and human bladder 
uroepithelium in in vivo (Figure 1) and in vitro (Figure 2) studies. These models were 
developed to study the pathogen-host interaction underlying GBS UTI. UPGBS bind more 
efficiently to bladder epithelial mucosa when compared with non-UPGBS (Ulett et al., 2010). 
Binding models of GBS UTI to study host cell interactions in vivo and in vitro have been 
derived from clinical studies conducted in the past five years. The largest of these clinical 
studies of GBS UTI to date was performed in the United States using a cohort of 387 patients 
with positive GBS cultures in urine. This study investigated the traits of UPGBS that cause 
acute UTI and ABU using detailed analysis of patients groups alongside serotyping 
comparisons, and risk factor analysis. The study also investigated the demographic data 
alongside standard diagnostic microbiological measures for the defined patient groups, 
which are summarized in Table 1. In this study, a total of 62 patients of the 387 patients with 
positive GBS urine culture had single-organism bacteriuria >104 cfu/ml concurrent with at 
least one UTI symptom and were defined as having probable GBS UTI. The most prevalent 
serotypes of GBS causing UTI in this study according to MS were serotypes V, Ia, and III, as 
shown in Table 2. Together, these serotypes accounted for 76% of GBS UTI cases. Serotype 
III GBS was the only serotype that was more frequently isolated from UTI case patients 
than from controls. Thus, in this study GBS UTI occurred mostly as uncomplicated cystitis in 
middle-aged women (>50 yrs) in the absence of chronic underlying disease but was 
associated with a prior history of UTI.  
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Fig. 1. UPGBS bound to bladder uroepithelium in a murine model of GBS cystitis (A–C, 
flattened bladder; D, native conformation). The arrows in panel D show bound UPGBS  
between folds of bladder uroepithelium. Panel E illustrates better bind of UPGBS to bladder 
mucosa compared with non-UPGBS although binding is not as efficient as uropathogenic 
Escherichia coli (UPEC) and levels of bacteriuria are simiular (F). Reproduced, along with 
Figure 2, with permission from (Ulett et al., 2010) courtesy of Oxford Journals. 
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Fig. 2. UPGBS (green) bound to human bladder cells (blue, nuclei; red F-actin) at 
multiplicities of infection of 50 (A) and 5 (B). Uninfected cells in (C). Measures of binding of 
UPGBS and non-UPGBS to T24 (D) and 5637 (E) cells shows higher binding of UPGBS.  
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Total  
Specimens 
(n=387)a 
GBS UTI Casesb  
Controlsd 
(n=51) 
P  
(All cases vs 
controls) 
UA +vec 
(n=31) 
UA NDc 
(n=31) 
All (n=62) 
Age (mean years; range) 46; 18-95 54; 19-82 52; 19-93 53; 19-93 30; 18-64 < 0.001g 
Female sex 322 (83) 25 (81) 27 (87) 52 (84) 46 (90) 0.002h 
Symptoms 
   
- Dysuria 68 (17.6) 18 (58.1) 17 (54.8) 35 (56.5) 0 (0) ND 
- Frequency 57 (14.7) 11 (35.5) 12 (38.7) 23 (37.1) 0 (0) ND 
- Flank pain 35 (9.0) 7 (22.6) 7 (22.6) 14 (22.6) 0 (0) ND 
- Fever 15 (4.0) 4 (13.0) 2 (6.0) 6 (10.0) 0 (0) ND 
- C/W cystitise 130 (33.6) 25 (80.6) 24 (77.4) 50 (81.0) 0 (0) ND 
- C/W pyleonphritisf 65 (16.8) 6 (19.4) 7 (22.6) 12 (19.0) 0 (0) ND 
Pregnant 99 (30.1) 1 (4) 5 (18.5) 6 (11.5) 35 (76)  
Possible Risk factors 
 
- Limited mobility 13 (3.4) 1 (3.2) 0 (0) 1 (1.6) 0 (0) 1.000 
- Diabetes mellitus 91 (23.5) 5 (16.1) 4 (12.9) 9 (14.5) 9 (17.6) 0.651 
- Chronic kidney disease 72 (18.6) 4 (12.9) 0 (0) 4 (6.5) 7 (13.7) 0.219 
- Indwelling urinary catheter 4 (1.0) 0 (0) 0 (0) 0 (0) 0 (0) ND 
- Altered mental status 14 (3.6) 3 (9.7) 2 (6.5) 5 (8.1) 0 (0) 0.063i 
- Prior History of UTI 76 (19.6) 9 (29.0) 9 (29.0) 18 (29.0) 6 (11.8) 0.032j 
Pure GBS isolated 207 (53.5) 31 (100) 31 (100) 62 (100) 15 (29.4) ND 
GBS count >107 cfu/L 319 (82.4) 31 (100) 31 (100) 62 (100) 0 (0) ND 
Mean GBS count (x 107/L) 4.7  3.6 7.4  3.5 6.1  3.1 6.7  3.4 0.5  0.3 ND 
UA done 210 (54.3) 31 (100) 0 (0) 31 (50) 9 (17.3) ND 
- Pyuria 114 (54.3) 31 (100) ND 31 (100) 0 (0) ND 
- Leukocyte esterase 122 (58.1) 31 (100) ND 31 (100) 0 (0) ND 
- Hematuria 74 (35.2) 21 (67.7) ND 21 (67.7) 2 (22) ND 
- +ve and C/W UTId-f 91 (43.3) 31 (100) ND 31 (100) 0 (0) ND 
 
 
Table 1. Patients who had GBS  isolated from urine during routine assessement for UTI at 
University of Alabama Hospital between August 2007-2008. NOTE. Data are no. (%) of 
patients, unless otherwise indicated; a. Consecutive urine specimens sent for culture, from 
which GBS  was isolated; b. Patients with ≥1 symptom(s) of UTI and pure growth of GBS  
>107 cfu/L; c. UA: +ve (consistent with UTI) positive leukocyte esterase and pyuria; ND not 
done; d. Subjects without symptoms from whose urine GBS  was isolated in counts <107/L; e. 
Symptoms consistent with (C/W) cystitis: dysuria and/or frequency; f. Symptoms C/W 
pyelonephritis: dysuria and/or frequency plus flank pain and/or fever >38ºC; g. By Mann–
Whitney U test; h. By Pearson 2 analysis. Gender comparisons performed using population 
data (equal group sizes) from the US Census Bureau for Birmingham (male-female ratio 
85.7); i. By Fisher’s exact test; j. By forward stepwise logistic regression subsequent to 
Pearson 2 analysis; Reproduced, with Table 2, with permission from (Ulett et al., 2009) 
courtesy of The American Society for Microbiology. 
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GBS 
Serotype 
All  
Specimens 
(n=387)a 
GBS UTI Casesb 
 
Controlsd 
(n=51) 
UA +vec 
(n=31) 
UA NDc 
(n=31) 
All 
(n=62) 
  n (%)   n (%)   n (%)   n (%)   n (%)
Ia 81 (21) 6 (19) 8 (26) 14 (23) 8 (16)
Ib 31 (8) 2 (7) 3 (10) 5 (8) 5 (10)
II 69 (18) 5 (16) 3 (10) 7 (11) 12 (24)
III 48 (12)e 8 (26) 5 (16) 13 (21)e 5 (10)
IV 24 (6) 2 (7) 1 (3) 3 (5) 5 (10)
V 125 (32) 8 (26) 12 (37) 20 (32) 10 (20)
VI 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
VII 0   (0) 0 (0) 0 (0) 0 (0) 0 (0)
VIII 2 (1) 0 (0) 0 (0) 0 (0) 1 (2)
NTf 7 (2) 0 (0) 0 (0) 0 (0) 5 (10)
IX 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
  
Table 2. Molecular serotypes of GBS that cause UTI, from the largest study of 387 patients 
with positive urine cultures for GBS to date. NOTE. Data are no. (%) of GBS  isolates, unless 
otherwise indicated; a. Consecutive urine specimens sent for culture, from which GBS  was 
isolated; b. Patients with ≥1 symptom(s) of UTI and pure growth of GBS  >107 cfu/L; c. UA: 
+ve (consistent with UTI) positive leukocyte esterase and pyuria; ND not done; d. Subjects 
without symptoms from whose urine GBS  was isolated in counts <107/L; e. Difference 
between the prevalence of serotype III among all GBS  UTI case patients and all other non-
GBS  UTI cases (n=325), significant by Pearson 2 analysis (P=0.026); f. Isolates were 
identified using antisera as: NT (3), II (2), IV (1) and V (1). 
3. Conclusions 
In summary, GBS is an important pathogen that causes serious infections in newborns, 
pregnant women, and elderly people with chronic illness. While early diagnosis and 
management of GBS among pregnant women can reduce the incidence of neonatal infection 
the prevalence of GBS disease in adult populations emphasizes the need for additional 
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preventative and therapeutic measures. Moreover, the emergence of antibiotic-resistant 
strains of GBS imposes a significant threat to the successful treatment of these infections. 
This is particularly relevant to GBS UTI, which is associated with relatively high rates of 
treatment failure and poor clinical outcomes (Munoz et al., 1992). Screening pregnant 
mothers for GBS ABU appears to be important in relation to the vertical transmission of GBS 
to infants however more research is needed to clarify this aspect of GBS UTI. An 
overarching and intriguing theme with GBS infection in humans is that GBS can efficiently 
colonize the genital tract of healthy adult women long-term without triggering apparent 
disease but, on the other hand, can also cause acute disease in some individuals. How this 
occurs is unknown.  
Research efforts to understand GBS pathogenesis should focus on the different strains of 
GBS that cause distinct clinical conditions of UTI such as ABU and cystitis in order to 
analyse the virulence traits that are associated with these infections. How these infections 
progress to disease in some individuals is completely unknown but acute inflammation in 
GBS UTI appears to differ mechanistically compared to that which occurs in other Gram-
negative UTI. Further longer-term surveillance studies of GBS UTI and ABU will help to 
better define the clinical features and serotypes associated with these infections. The 
question of how GBS might adapt to the niche environment of the urinary tract is another 
intriguing and unanswered question. A better understanding of the molecular mechanisms 
used by GBS to colonise uroepithelium and persist in the bladder will be an important area 
for future investigation. Broader utilization of appropriate in vivo and in vitro models 
beyond those already characterized will help to answer these questions. One area for 
investigation, for example, would be to use human urine as a growth medium to study 
fitness traits of UPGBS as has been performed for other uropathogens to discover key 
elements of UTI disease pathogenesis and how some successful uropathogens persist within 
the urinary tract in the absence of direct binding to cellular targets. Such studies will pave 
the way to develop new preventive and perhaps therapeutic strategies for GBS UTI. While 
many of the current strategies have focused on the development of vaccines for prevention 
of GBS disease (Maione et al., 2005) their potential for reducing GBS disease burden due to 
UTI is unknown. Identification of alternate drug targets would also be a goal of future 
research. Elucidation of the mechanisms that underlie GBS disease pathogenesis is pivotal 
for the identification of such alternate drug targets and also in the development of novel 
vaccines. A better  understanding of how GBS  regulates expression of its virulence survival 
factors is imperative. Finally, the underlying phenotypic basis for UPGBS could be gained 
by comparing GBS isolated from asymptomatic infection to cystitis strains by comparative 
genome sequencing approaches. Discoveries from such research may challenge the existing 
paradigms and reveal surprising insights into the versatile nature of this important human 
pathogen. 
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